Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Purchased by Walleye Capital LLC

Walleye Capital LLC boosted its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) by 101.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 141,127 shares of the company’s stock after buying an additional 71,127 shares during the period. Walleye Capital LLC owned 0.25% of Design Therapeutics worth $871,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DSGN. American Century Companies Inc. increased its stake in Design Therapeutics by 19.9% during the fourth quarter. American Century Companies Inc. now owns 39,115 shares of the company’s stock worth $241,000 after acquiring an additional 6,481 shares during the last quarter. Geode Capital Management LLC raised its holdings in Design Therapeutics by 7.1% in the third quarter. Geode Capital Management LLC now owns 758,550 shares of the company’s stock valued at $4,081,000 after buying an additional 50,579 shares during the period. Barclays PLC lifted its position in Design Therapeutics by 34.2% during the third quarter. Barclays PLC now owns 96,635 shares of the company’s stock valued at $520,000 after buying an additional 24,602 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Design Therapeutics by 186.9% during the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company’s stock worth $219,000 after buying an additional 26,503 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Design Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 264,675 shares of the company’s stock worth $1,633,000 after acquiring an additional 7,243 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Design Therapeutics Trading Up 2.6 %

NASDAQ:DSGN opened at $3.59 on Tuesday. Design Therapeutics, Inc. has a twelve month low of $2.60 and a twelve month high of $7.77. The firm has a market capitalization of $203.78 million, a price-to-earnings ratio of -4.22 and a beta of 1.82. The firm’s fifty day simple moving average is $4.18 and its 200 day simple moving average is $5.07.

Design Therapeutics (NASDAQ:DSGN) last posted its earnings results on Monday, March 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. On average, analysts predict that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.